ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Investigation of the modulatory effects of fabomotizole and/or sertraline on cisplatin nephrotoxicity via in vivo and in vitro approaches: insights into the role of Sig-1R/ERK1/2 signaling in regulating mitochondrial dynamics and apoptotic cellular death.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial dynamics disruption and the proapoptotic proteins activation are reported to be the major protagonists of the pathological alterations in cisplatin-induced nephrotoxicity. This study assessed the impact of modulating Sig-1R activity by fabomotizole and/or sertraline on cisplatin nephrotoxicity focusing on the regulation of renal mitochondrial homeostasis and apoptotic cellular death. Four groups of rats received a single cisplatin injection, and were assigned to: cisplatin control, sertraline-treated, fabomotizole-treated, sertraline + fabomotizole-treated groups, along with a fifth normal control group. In parallel, HEK293 cells were used to evaluate the effects of the tested agents on renal cell viability. Elevated concentrations of sertraline reduced HEK293 cell viability. Additionally, sertraline maintained the noxious effect of cisplatin on mitochondrial homeostasis and renal apoptosis in rats. In contrast, fabomotizole improved cell viability in HEK293 cells exposed to cisplatin. It preserved the structural integrity of the renal tubular cells and suppressed plasma levels of NGAL, BUN and creatinine in cisplatin-intoxicated rats. Electron microscopy revealed that fabomotizole restored mitochondrial homeostasis, as shown by increased mitochondrial density. Mechanistically, fabomotizole downregulated the mitochondrial fission mediator Drp1 while upregulating the mitochondrial fusion mediator Mfn1; this was reflected on the mitochondrial function by reinstating renal ATP content. Furthermore, fabomotizole hindered ERK1/2 activation and reduced the proapoptotic proteins, Bax and Bak along with caspase 3 activity. As demonstrated by the Sig-1R antagonistic effect of sertraline, which notably negated fabomotizole's renoprotective potential, fabomotizole's capacity to preserve stable mitochondrial dynamics and hamper apoptosis following cisplatin nephrotoxicity may be ascribed to its Sig-1R activation-mediated ERK 1/2 inhibition.
Indexed as
Identifiers
42154013What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.